Endobronchial Metastasis Research Articles

Can endobronchial metastasis from uterine leiomyosarcoma be managed by sleeve lobectomy? A case report and systematic review

Uterine Leiomyosarcoma (uLMS) is an exceptionally rare yet aggressive tumor, characterized by poor clinical outcomes. It exhibits a high potential for metastasis, even long after apparent remission. Surgical excision remains the cornerstone of treatment for localized uLMS and isolated metastatic cases.

Endobronchial metastasis of melanoma: a clinical case

Background. Despite high metastatic potential, melanoma rarely metastasizes to the tracheobronchial tree, accounting for 4.5-5.3% of cases. Therefore, epidemiological, clinical, and pathological features, as well as treatment, are based on individual reports in the literature.
 Aim. To present a clinical case of isolated endobronchial metastasis of melanoma.
 Materials and methods. A 67-year-old patient underwent surgical treatment for stage IIb pT2N0M0 melanoma of the IV toe of the left foot in August 2014. Histological study showed the ulcerated epithelioid cell pigment melanoma of level III invasion according to Clark classification, and the Breslow thickness was 2 mm. No adjuvant treatment was administered.
 Results. During the follow-up, no signs of disease progression were found. In December 2022, the patient survived a new coronavirus infection. In February 2023, the patient reported dyspnea on exertion, dry cough, and hemoptysis. Fibrobronchoscopy in the upper lobe of the left lung in one of the subsegmental branches revealed pigmentation of the bronchial mucosa of gray and black in some spots. Based on the results of cytological examination, metastasis of pigment epithelioid cell melanoma was diagnosed. According to imaging studies, no other manifestations of melanoma progression were identified. The patient received immunotherapy with pembrolizumab for 6 months with no signs of metastasis progression.
 Conclusion. Isolated endobronchial metastasis of melanoma is uncommon. The latency period in the presented case was 103 months. The clinical presentation included dyspnea during physical exertion, dry cough, and episodes of hemoptysis. The main diagnostic method is fibrobronchoscopy with biopsy for morphological examination. Imaging methods are necessary to establish the spread of the tumor.

A case of endobronchial metastasis of colon cancer mimics sarcoidosis, and a review of related literature.

Endobronchial metastases (EBM) are defined as bronchoscopically visible lesions histopathologically identical to extrapulmonary tumors. We summarized the literature on endobronchial metastasis of colorectal cancer and give a brief review. We present a rare case with an episode mistaken for sarcoidosis and unexpectedly identified as colon cancer by bronchoscopic biopsy. A 53-year-old man with dry cough and dyspnea had diffuse micro lung nodules and lymphadenopathy on CT and PET/CT. He was diagnosed with sarcoidosis and took steroid therapy, but the symptoms could not be alleviated. Bronchoscopy was suggested. He was finally identified with colon cancer by bronchoscopic biopsy, which was confirmed by endoscopic biopsy. We summarise the clinical manifestations, imaging, prognosis of EMB of colorectal cancer. EBM are rare. Colorectal cancer is common in EBM and the frequency is increasing. EBM should be distinguished from primary lung cancer, sarcoidosis.

The case of successful treatment of a patient with endobronchial intraluminal metastasis of kidney cancer

Tracheal cancer accounts for less than 0.2 % of the total number of oncological diseases. The medical literature describes isolated cases of metastatic lesions of the trachea and bronchi from distant organs. Metastasis of kidney cancer is observed most often in the absence of early detection of the tumor. We present a case of successful treatment of intraluminal metastasis of kidney cancer into the trachea.

Endobronchial metastasis secondary to occulting renal cell carcinoma: literature review and a rare case report

BackgroundEndobronchial Metastasis from extrathoracic tumors is a rare neoplasm that accounts for approximately 1.1% of total endobronchial malignancies. The most common primary tumors associated with EBM are from the colorectal, breast, and kidney regions. Although it represents a late manifestation in the context of tumor progression, it can rarely antedate the diagnosis of the primary tumor.Case presentationA 67-years-old male was referred from another city hospital to our thoracic surgery department due to a 4-months history of hemoptysis and productive cough. A chest X-ray and computed tomography scan showed a soft-tissue mass within the left main bronchus and atelectasis of the anterior segment of the left upper lobe. Furthermore, a flexible bronchoscopy revealed a hypervascular lesion occluding completely the left upper lobe bronchus. The patient underwent lobectomy and pathological examination suggested endobronchial metastasis from clear cell renal cell carcinoma. A second computed tomography scan of the abdomen and pelvis showed a well-defined mass arising from the lateral aspect of the right kidney; therefore, the patient underwent right radical nephrectomy three weeks later and pathology confirmed the diagnosis of clear renal cell carcinoma with endobronchial metastasis.ConclusionDespite its rarity, physicians should consider the possibility of endobronchial metastases in the setting of endobronchial lesions. Proper diagnostic approaches should also be considered to rule out the potential of asymptomatic extrathoracic neoplasms. In this manuscript, we aimed to report a rare case -the first from Syria to our knowledge- of an endobronchial metastasis that preceded the diagnosis of renal cell carcinoma. Importantly, we reviewed the existing literature and discussed the diagnostic and treatment approaches.

Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study.

Kinase inhibitors (KI) and antibodies targeting the VEGF pathway are approved in a broad spectrum of cancers and associated with an increased risk of bleeding and thromboembolic events (TE). The use of direct oral anticoagulants (DOACs) apixaban and rivaroxaban is increasing in cancer patients, but limited data are available for patients receiving anti-VEGF agents. To assess safety of DOAC with concomitant anti-VEGF agents, a retrospective chart review of all patients receiving concomitantly DOAC and anti-VEGF agents was performed from 2013 to 2020 in our center. Data on demographics, safety, and time on treatment were collected. Main outcome was safety (bleeding and thromboembolic events). Of 92 patients (median age 66years (IQR: 59-72)), 40 were treated with KI and 52 with bevacizumab. The most frequent primary tumor sites were colon/rectum (24%), kidney (21%), ovary (13%), lung (11%), soft tissue sarcoma (10%), and thyroid (9%); 2% had brain metastases. Apixaban 5mg bid (n = 41) or rivaroxaban 20mg daily (n = 51) were given for TE (65%), atrial fibrillation (32%), or other indications (3%). The median duration of concomitant treatment was 4.8months (95%CI: 0.7-50.0) with bevacizumab and 11.7months (95%CI: 0.1-53.8) with KI. Grade ≥ 3 bleeding events occurred in 5 patients (5%): 4 patients receiving bevacizumab (one grade 5 upper digestive tract bleeding and three grade 3 rectal or vaginal hemorrhages) and 1 patient under cabozantinib for kidney cancer with endobronchial metastasis (grade 3 hemoptysis). Grade ≥ 3 TE occurred in 8 patients (9%): 7 patients receiving bevacizumab (including one grade 5 pulmonary embolism), and one patient receiving sunitinib (grade 3 pulmonary embolism). Median time-to-event (bleeding or thrombotic event) was not reached (NR) (95%CI: 76.9-NR) for KI and 86.9months (95%CI: 42.9-148.0) for bevacizumab. CONCLUSIONSAND RELEVANCE: In our experience, the use of DOAC was safe in selected patients treated with KI, but unclear with bevacizumab. More data are needed to endorse guidelines in this specific group of patients.

929: ENDOBRONCHIAL METASTASIS FROM OSTEOSARCOMA: TREATMENT WITH CRYOTHERAPY AND ARGON PLASMA COAGULATION

Introduction: Osteosarcoma is the most common primary malignant tumor of the bone. Pulmonary metastasis is frequently seen as a relapse in approximately 80% of patients; however, endobronchial metastasis is very rare. We present a case of endobronchial osteosarcoma in a young man. Description: A 20-year-old male non-smoker with a history of treatment-refractory metastatic osteosarcoma presented with shortness of breath, dry cough, and episodes of hemoptysis for a few days. On presentation, vital signs were significant for tachycardia (HR 113/min) and tachypnea (RR 24/min). Chest CT scan showed no pulmonary embolism but revealed bilateral pulmonary and pleural metastases with severe narrowing of the right upper lobe pulmonary artery segmental branches secondary to metastases. At fiberoptic bronchoscopy, there was complete obstruction of the right upper lobe apical and posterior segments by a dark red vascular appearing tumor. Cryotherapy was performed to destroy abnormal tissue, along with balloon occlusion. Coagulation using an Argon Plasma Coagulation (APC) was performed in the lung. Post-treatment findings showed improved lumen size. The patient tolerated the procedure well and had remarkable improvement in symptoms. Biopsy of the endobronchial tumor showed metastatic sarcoma, similar to the patient’s prior high-grade pleomorphic sarcoma. Discussion: Airway obstruction may be extrinsic, intrinsic, or mixed; fixed or dynamic; and benign or malignant. It may present with a variety of symptoms ranging from mild shortness of breath to respiratory failure. There are few published case reports of endobronchial obstruction secondary to osteosarcoma. Bronchoscopy (either rigid or flexible) is always necessary for assessing airway obstruction. Dilation is immediately effective for intrinsic and extrinsic compression, but results are typically not sustained. Cryotherapy relies on repeated freeze-thaw cycles using extreme cold (below –40°C) to destroy tissue and tumor and can be used via both rigid and flexible bronchoscopes. APC is a mode of noncontact electrocoagulation that is increasingly used as an alternative to contact electrocautery and noncontact laser therapy. Often, the best therapeutic approach appears to include a combination of several treatment approaches as demonstrated in our patient.

RENAL CELL CARCINOMA PRESENTING AS LUNG COLLAPSE

RENAL CELL CARCINOMA PRESENTING AS LUNG COLLAPSE

Hot Gloved Finger Sign in Endobronchial Metastasis From Hepatocellular Carcinoma on FDG PET/CT.

Endobronchial metastasis from hepatocellular carcinoma is exceedingly rare. We describe FDG PET/CT findings in a case with isolated endobronchial metastasis from hepatocellular carcinoma 13 years after hepatectomy. The endobronchial metastasis appeared as hypermetabolic branching tubular opacities, producing a hot gloved finger sign on FDG PET/CT. This case indicates that the hot gloved finger sign may be suggestive of extensive endobronchial growing of a malignant condition but not endobronchial mucoid plug.

Morphology quiz: Bronchial washing cytology from flexible bronchoscopy.

The aim of this observation is to aware cytologists on melanoma cells identification in bronchial washing, from an endobronchial metastasis of malignant melanoma. Images of CT scan and flexible bronchoscopy are also provided. Differential diagnosis and additional analyses (molecular biology) are also mentioned and discussed.

Endobronchial brachytherapy as definitive treatment for endobronchial metastasis after surgery of non-small cell lung cancer

BackgroundEndobronchial metastasis is a very rare type of recurrence after lung cancer surgery. Surgical intervention may be difficult to perform due to the postoperative reduction in the activities of daily living (ADL) and the invasiveness associated with redo surgery. In such cases, endobronchial brachytherapy (EBBT) plays an important role not only as a palliative treatment, but also as a definitive treatment with curative intent.Case presentationThree men (64, 69, and 74 years old) underwent combination therapy of external beam radiation therapy (EBRT) and EBBT for endobronchial metastasis after lobectomy of stage I–II non-small cell lung cancer (NSCLC): 2 cases of squamous cell carcinoma and 1 of adenocarcinoma. We used a special source-centralizing applicator for EBBT to avoid eccentric distribution of the radiation dose. Follow-up was considered to start from the end of brachytherapy. None of our patients experienced severe adverse events, and none needed extensive outpatient treatment. Local control was achieved in all cases by a bronchoscopic evaluation. All patients were alive after 31, 38, and 92 months of follow-up, respectively. In the adenocarcinoma patient, two metastases to the lung were discovered 3 years after EBBT, and the patient underwent partial wedge resection.ConclusionsEBBT may be a promising treatment with curative intent for endobronchial metastasis after surgery of NSCLC.

Cytology Detects Endobronchial Metastasis from Appendiceal Signet-Ring Cell Carcinoma in the Absence of Radiographic Lung Masses: A Case Report

Abstract Introduction/Objective Endobronchial metastasis (EBM) is uncommon, with a reported prevalence of 2% in cases of non-lung primary malignancies. The most frequently observed carcinomas in EBM are from breast, colon, and renal origins. We present a rare case of endobronchial metastasis from a primary tumor of the appendix without lung masses by computed tomography (CT). Methods/Case Report An 83-year-old woman with signet-ring cell carcinoma of the appendix underwent right hemicolectomy and chemotherapy. Two years later, she returned with intractable nausea and vomiting, and respiratory distress. CT of the chest demonstrated diffuse bilateral pulmonary opacities without lung masses. CT of the abdomen showed peritoneal carcinomatosis. Cytology of ascitic fluid displayed metastasis of the patient’s known appendiceal tumor. Bronchoscopy found significant friable debris appearing to be tumor tissue and occluding multiple bronchioles in the right lung. A bronchoalveolar lavage (BAL) specimen from the right lung was sent for liquid-based cytology, which revealed a few atypical cells with eccentric nuclei and intracytoplasmic vacuoles, abundant macrophages, degenerated mixed inflammatory cells, and scattered bronchial epithelial cells. Cell block demonstrated signet-ring cells mimicking macrophages and infiltrating into small fragments of bronchiolar wall. The signet-ring cells were morphologically similar to those found in the ascitic fluid and the patient’s primary tumor, and were highlighted by mucicarmine stain and immunohistochemical stains for CDX-2 and CK20, but not CK7. Results (if a Case Study enter NA) N/A Conclusion Collectively, the findings supported the diagnosis of endobronchial metastasis of signet-ring cell carcinoma from the lower gastrointestinal tract, i.e. the patient’s known appendiceal primary. Our case demonstrates a rare endobronchial metastasis of a primary neoplasm of the appendix, an important diagnostic consideration when evaluating respiratory distress in patients with such cancer histories. We have described the significant role of BAL cytology to uncover endobronchial metastases without lung masses by CT, and illustrated the finding of signet-ring cells mimicking macrophages in a BAL cytology specimen.

Endobronchial metastasis of urinary bladder carcinoma

Introduction: Bladder cancer is the 12th most common cancer type worldwide. The most common symptom is painless hematuria. The most common sites of distant metastasis are liver (47%), lung (45%) and bone (32%), respectively. Case report: 73-year-old male patient was admitted with the complaint of hematuria. With a preliminary diagnosis of bladder cancer transurethral resection of tumour (TUR-B) was performed and pathology reported invasive urothelial carcinoma. The patient applied to the pulmonary diseases outpatient clinic with the complaint of cough and wheezing. Bronchoscopy was performed with a pre-diagnosis of bladder cancer metastasis. Multiple biopsies from EBL reported in accordance with urothelial carcinoma metastasis. Result: Urothelial carcinoma of the bladder may present with different pulmonary involvement. Although endobronchial metastasis is a rare condition; it should always be kept in mind in patients with respiratory system complaints. Keywords: endobronchial metastasis; bladder carcinoma; urothelial carcinoma; pulmonary involvement.

METASTATIC COLORECTAL CANCER PRESENTING AS AN OBSTRUCTING ENDOBRONCHIAL LESION

TOPIC: Pulmonary Manifestations of Systemic Disease TYPE: Medical Student/Resident Case Reports INTRODUCTION: Colorectal cancer is one of the most common malignancies worldwide with the pulmonary parenchyma a common site for distant metastasis. Colorectal endobronchial metastases, however, are exceedingly rare. We present a patient with previously resected colon cancer who was found to have an obstructing endobronchial colorectal metastasis. CASE PRESENTATION: A 66-year-old male with a 12 pack-year smoking history presented with dyspnea. On routine colonoscopy 4 years prior, he was diagnosed with moderately differentiated colorectal adenocarcinoma with negative tumor margins and without any lympho-vascular involvement. Imaging was without evidence of regional or distant metastases so he underwent hemicolectomy. Medical oncology recommended no adjuvant chemotherapy and 1 year follow-up. The patient did not follow-up. Four years later, he presented with fever, dyspnea, cough, and pleuritic chest pain. CT pulmonary angiography demonstrated a RUL mass with RML lobe collapse, a moderate right-sided pleural effusion, and no pulmonary embolism. He was started on empiric antibiotics. Thoracentesis revealed an exudative effusion with negative cultures and cytology. Bronchoscopy demonstrated a fungating endobronchial lesion completely occluding the right middle lobe for which cryobiopsy and cryo-excision were performed. Pathology was consistent with metastatic moderately differentiated colorectal adenocarcinoma, with morphology and histology identical to his prior colorectal cancer. Transbronchial needle aspiration using endobronchial ultrasound of the station 7 mediastinal lymph node was negative for malignant cells. Patient left against medical advice before further work-up was completed. DISCUSSION: About 20% of patients with colorectal cancer have distant metastases at presentation, with the lungs being a common site, usually involving the pulmonary parenchyma and very rarely as an endobronchial lesion. In fact, endobronchial metastases from extra-thoracic malignancies account for 1% of all endobronchial tumors, with the most common being colorectal, breast and renal. These patients may present with a variety of non-specific respiratory symptoms. It is also not uncommon for endobronchial metastasis to occur after resection of the primary tumor and without other signs of metastases. One should consider the possibility of endobronchial involvement of a tumor in a patient with a history of an extra-thoracic malignancy who presents with vague respiratory symptoms, as timely bronchoscopic intervention can improve quality of life and help mitigate the risk of post obstructive complications. CONCLUSIONS: Endobronchial metastasis from extra-thoracic malignancies are very rare, accounting for 1% of all endobronchial tumors. Diagnosis can be difficult due to vague respiratory complaints. Bronchoscopic intervention can assist in diagnosis, management, and it can lead to substantial improvement in pulmonary symptoms. REFERENCE #1: Akoglu S, Uçan ES, Celik G, et al. Endobronchial metastases from extrathoracic malignancies. Clin Exp Metastasis. 2005;22:587–591. REFERENCE #2: Coriat R, Diaz O, de la Fouchardiere C, et al. Endobronchial metastases from colorectal adenocarcinomas: clinical and endoscopic characteristics and patient prognosis. Oncology. 2007;73:395-400. REFERENCE #3: Lin CY, Chung FT. Central airway tumors: interventional bronchoscopy in diagnosis and management. J Thoracic Dis. 2016;8(10):E1168-E1176. DISCLOSURES: Speaker/Speaker's Bureau relationship with Boehringer-Ingelheim Pharmaceuticals Please note: $5001 - $20000 by Jaime Betancourt, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Vapotherm, Inc Please note: $5001 - $20000 by Jaime Betancourt, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Boehringer-Ingelheim Pharmaceuticals Please note: 2014-Present Added 04/21/2021 by Jaime Betancourt, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Vapotherm, Inc Please note: 2019-Present Added 04/21/2021 by Jaime Betancourt, source=Web Response, value=Honoraria Advisory Committee Member relationship with Vapotherm, Inc Please note: 2020 Added 04/21/2021 by Jaime Betancourt, source=Web Response, value=Honoraria No relevant relationships by Ken Dekitani, source=Web Response No relevant relationships by Michael Lewis, source=Web Response No relevant relationships by Roberto Mempin, source=Web Response No relevant relationships by Scott Oh, source=Web Response

Endobronchial Metastasis of Renal Carcinoma: A Case Report and Review of Previous Literature.

The definition of endobronchial metastasis (EBM) lacks clarity because it is currently based on the judgments of surgeons; it is rare in patients with nonpulmonary malignancies. Although EBM represents an advanced stage of malignancy, it does not necessarily indicate a poorer prognosis than that for its primary tumors. The present study defines EBM as bronchoscopy-visible lesions with histologically confirmed primary extrapulmonary tumors, excluding those primary lung tumors with involvement of the bronchial lumen. A bronchoscopy and biopsy provide strong proof for diagnosis. Complete surgical resection is the best choice for patients with EBM. This study analyzed the case of a 69-year-old male patient who had undergone a radical left nephrectomy several years previously after the identification of a bronchoscopy-visible lesion in the left main bronchus. The lesion was initially diagnosed as an angiogenic tumor but was eventually confirmed by surgical biopsy as EBM from the left kidney. After diagnosis, the patient underwent a left pneumonectomy. The analysis of this case focused on diagnosis, symptoms, radiographic findings, treatment, and prognosis. A review of the previous literature relating to EBM was also conducted.

Phase I study of transarterial chemoembolization of lung metastases.

3602 Background: Lung chemoembolization (via the bronchial or pulmonary artery) is a new treatment option for unresectable and unablatable lung metastases. Methods: 10 patients with unresectable and unablatable lung, endobronchial, or mediastinal metastases, who failed systemic chemotherapy, were enrolled in this single center, single arm, phase I trial. Pulmonary and bronchial angiography was performed in all patients, to determine the blood supply to the lung metastases. Based on the angiographic findings, bronchial or pulmonary artery chemoembolization was performed, using a lipiodol / mitomycin emulsion, followed by spherical particles. Technical success, safety, efficacy, and pharmacokinetics were evaluated. Wilcoxon signed-rank test was used to compare change in size of treated versus untreated tumors. Results: On angiography, all patients had lung metastases that were hypervascular compared to normal lung. 90% of patients had lung metastases supplied by the bronchial artery, and 10% were supplied by the pulmonary artery. Technical success rate of intra-tumoral drug delivery was 100% (95% CI: 76-100%). There were no severe adverse events, and all patients met criteria for discharge 4 hours post procedure. Response rate of treated lesions was 10% by RECIST and 40% by PERCIST. Treated tumors were mostly stable to decreased in size after chemoembolization (median change in size: 0%; IQR: -11% to 2%; mean: -4%), and untreated tumors were mostly increased in size (median change in size: 10%; IQR: 0% to 17%; mean 9%; p= 0.02). Intra-tumoral lipiodol retention at 4-6 weeks was correlated with decreased tumor size and metabolic activity. Pharmacokinetics showed that 45% of the mitomycin dose underwent burst release in 2 minutes, and 55% of the dose was retained intratumorally with a half-life > 5 hours. Initial tumor-to-plasma ratio of mitomycin concentration was 380. Half-life of intratumoral lipiodol retention was 16 days. In vitro experiments showed 50% emulsion separation in 6.2 days, and 50% drug release in 7.1 hours. Conclusions: Lung chemoembolization can safely treat lung, mediastinal, and endobronchial metastases, with minimal systemic toxicity. High intratumoral drug concentrations after chemoembolization can overcome chemoresistance. Clinical trial information: NCT04200417.

Endoscopic semiotics of metastatic bronchial tumors

Aim. To study the possibilities of bronchoscopy in the detection and evaluation of metastatic lung tumors.
 Materials and methods. From 2017 to September 2020, 3719 bronchoscopies, including 1081 biopsies during bronchoscopy were performed at the Blokhin National Medical Research Center of Oncology. According to the results of the morphological verification, 40 patients had been diagnosed with lung metastasis.
 Results. Endobronchial metastatic tumors from extrapulmonary malignancies are quite rare. After had studying 40 cases of metastatic bronchial tumors, we found that the most commonly primary malignancies associated with endobronchial metastases were breast cancer (12 patients), colorectal cancer (6 patients) and thyroid cancer (4 patients). All patients who had been diagnosed with the pathology during the bronchoscopy had been required to make a biopsy for the purpose of morphological verification.
 Conclusion. The value of bronchoscopy lies in the possibility not only of the detailed visual studying and detecting the tumor pathology of the bronchial tree, but also of obtaining material for morphological analysis. In this regard, the role of biopsy during bronchoscopy is extremely important. In the visual signs of tumor lesion, it is necessary to take multiple biopsies from different parts of the tumor.

A rare presentation of endobronchial metastasis from renal cell carcinoma resected 120 months after nephrectomy.

Introduction: Multipl extrapulmonary tumors can metastasize to the bronchus. Endobronchial Metastases (EBM) should be distinguished from these tumors because of their poor prognosis and different treatments. Case presentation: A 70-year-old male patient was admitted with thorax computed tomography, which was taken with the complaints of increasing cough and weight loss. The patient who had a history of left nephrectomy due to renal cell carcinoma 10 years ago did not have a history of receiving postoperative chemotherapy/radiotherapy. In bronchoscopy, the right lung upper lobe anterior subsegment entry was obliterated with an endobronchial lesion. The histopathological appearance was consistent with clear cell renal cell carcinoma metastasis Conclusion: This case is presented to emphasize that EBM may mimic primary lung cancers especially with respiratory symptoms. Ten years’ time interval is the longest period between radical nephrectomy and EBM in literature.

Endobronchial Metastasis of Colorectal Carcinoma

Background: Endobronchial metastasis is an infrequent secondary location of an extra thoracic cancer. Colorectal cancer is one of the most affected primary tumours. Case presentation: We report the clinical case of a patient who has had endobronchial metastasis of a adenocarcinoma of the colon, confirmed by mass biopsy. Surgical treatment was indicated after chemotherapy cures. The patient is currently asymptomatic 33 months after treatment. Conclusion: Endobronchial metastasis is a rare entity, occurring after years of primary disease progression. Surgery allows for prolonged survival and disease control.

A Case of Lung Adenocarcinoma with Postoperative Endobronchial Metastasis

A Case of Lung Adenocarcinoma with Postoperative Endobronchial Metastasis